Patent protection belimumab?

How long do the belimumab patents run?
Belimumab’s core patents, filed in the early 2000s, expire 20 years from their earliest filing dates, roughly 2027‑2030. The biologic exclusivity granted by the FDA adds another 12 years, so commercial protection lasts until about 2034‑2035. [1]

What does the patent portfolio actually cover?
The patents cover the antibody’s amino‑acid sequence, its production process, and the use of the drug for systemic lupus erythematosus (SLE). They also include specific formulations and dosage regimens that were first approved. [1]

Can a biosimilar enter the market before the patents expire?
Biosimilar approval requires that all relevant patents be cleared or that the applicant has a valid license. Because the key composition patents are still active, a biosimilar cannot gain approval without a license or a successful litigation challenge. [1]

Are there any litigation or challenges to these patents?
So far, no major injunctions or invalidation suits have been reported. The patents remain in force, and GlaxoSmithKline and Pfizer retain their exclusive rights. [1]

When does the 12‑year biologic exclusivity end?
Exclusivity is tied to the first FDA approval, which was in 2011. That period ends in 2023, but it does not affect the underlying patents. Even after exclusivity lapses, the patents still block generic entry until their expiration. [1]

Who holds the belimumab patents?
GlaxoSmithKline (GSK) and Pfizer jointly hold the main patents and the associated licensing agreements. [1]

What does this mean for pricing?
Because the patents and exclusivity remain, the manufacturer can maintain premium pricing. Once patents expire, competition from biosimilars could lower prices, but this is still many years away. [1]

Will competitors produce a cheaper version soon?
Not until the patents lapse or are licensed. The next potential entry point is the 2030‑2035 window when all patents expire, after which biosimilar developers may apply for approval. [1]

Where can I find the most up‑to‑date patent details?
DrugPatentWatch.com tracks the belimumab patent portfolio and updates on filings, expirations, and legal status. Check the site for the latest dates and litigation status. [1]